The circadian clock protein REVERBα inhibits pulmonary fibrosis development.
Peter S CunninghamPeter MeijerAlicja NazgiewiczSimon G AndersonLee A BorthwickJames BagnallGareth B KitchenMonika LodygaNicola BegleyRajamiyer V VenkateswaranRajesh ShahPaul F MercerHannah J DurringtonNeil C HendersonKaren Piper-HanleyAndrew J FisherRachel C ChambersDavid A BechtoldJulie E GibbsAndrew S LoudonMartin K RutterBoris HinzDavid W RayLaurence PearmainPublished in: Proceedings of the National Academy of Sciences of the United States of America (2019)
Pulmonary inflammatory responses lie under circadian control; however, the importance of circadian mechanisms in the underlying fibrotic phenotype is not understood. Here, we identify a striking change to these mechanisms resulting in a gain of amplitude and lack of synchrony within pulmonary fibrotic tissue. These changes result from an infiltration of mesenchymal cells, an important cell type in the pathogenesis of pulmonary fibrosis. Mutation of the core clock protein REVERBα in these cells exacerbated the development of bleomycin-induced fibrosis, whereas mutation of REVERBα in club or myeloid cells had no effect on the bleomycin phenotype. Knockdown of REVERBα revealed regulation of the little-understood transcription factor TBPL1. Both REVERBα and TBPL1 altered integrinβ1 focal-adhesion formation, resulting in increased myofibroblast activation. The translational importance of our findings was established through analysis of 2 human cohorts. In the UK Biobank, circadian strain markers (sleep length, chronotype, and shift work) are associated with pulmonary fibrosis, making them risk factors. In a separate cohort, REVERBα expression was increased in human idiopathic pulmonary fibrosis (IPF) lung tissue. Pharmacological targeting of REVERBα inhibited myofibroblast activation in IPF fibroblasts and collagen secretion in organotypic cultures from IPF patients, thus suggesting that targeting of REVERBα could be a viable therapeutic approach.
Keyphrases
- pulmonary fibrosis
- idiopathic pulmonary fibrosis
- induced apoptosis
- endothelial cells
- risk factors
- transcription factor
- interstitial lung disease
- pulmonary hypertension
- bone marrow
- stem cells
- endoplasmic reticulum stress
- end stage renal disease
- newly diagnosed
- escherichia coli
- ejection fraction
- poor prognosis
- chronic kidney disease
- cancer therapy
- dendritic cells
- cross sectional
- binding protein
- depressive symptoms
- immune response
- small molecule
- cell proliferation
- high glucose
- prognostic factors
- staphylococcus aureus
- resting state
- diabetic rats
- epithelial mesenchymal transition
- cell adhesion
- patient reported
- genome wide identification